Navigation Links
Paul Capital Healthcare Leads Panel on Strategic Financing
Date:6/8/2008

NEW YORK and LONDON, June 9 /PRNewswire/ -- Paul Capital Healthcare today announced that London-based partner Ken Macleod, Ph.D., will moderate a panel on strategic biotechnology financing at the BioFinance and BioInnovate Europe 08 conference. Designed to familiarize participants with how to use revenue streams as a strategic approach to financing, the panel, "Feeding the Beast: Structured Revenue Financing as a Strategy for Meeting Biotechnology's Capital Needs," is scheduled for 3:00 pm BST today. The conference, which is sponsored by the Biotechnology Industry Association, will be held at the Royal College of Physicians in London.

In addition to Dr. Macleod, the panel also will include Kristian Wiggert, Partner in the London office of Morrison & Foerster, and Steven Powell, Ph.D., Chief Executive Officer of Plethora Solutions Holdings PLC. Dr. Macleod will provide an overview and case studies of royalty and structured revenue financing transactions, Mr. Wiggert will discuss the legal considerations of these transactions and Dr. Powell will speak on the strategic rationale and mechanics of his company's recent revenue interest agreement with Paul Capital Healthcare.

"Structured revenue financing and royalty monetization transactions are becoming a standard financing strategy because they provide access to non- dilutive capital under flexible terms that can be structured to meet diverse objectives," said Dr. Macleod. "Companies and institutions can structure these transactions to provide capital for near-term initiatives while retaining a substantial portion of the long-term value and upside potential of their royalty and revenue streams. This panel presentation is designed to provide participants with real-life examples of how these transactions fit into an overall financial and asset management strategy and the opportunity to learn from those with first-hand knowledge of the process."

About Paul Capital Healthcare and Paul Capital Partners

Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $940 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London, Hong Kong, and Sao Paolo.

Contact Information:

Paul Capital Healthcare Tel: +44 (0) 20 7514 0754

Ken Macleod, Partner

Lazar Partners Tel: +1-646-871-8487

Stephanie Seiler Tel: +1-206-713-0124

Email: sseiler@lazarpartners.com


'/>"/>
SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace Releases the 2008 BioCapital(TM) Hotbed Campaign
2. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
3. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
4. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
5. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
6. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
7. Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007
8. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
9. Launch of Fountain Healthcare Partners, a Life Science Venture Capital Firm
10. Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... education provider of women’s health, primary care, and specialty education, announced today ... Medical Education (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and ...
(Date:2/22/2017)... , Feb. 22, 2017 Origin (Origin Agritech, LLC, ... trait and seed provider, and Arcadia (Arcadia ... that develops and commercializes agricultural productivity traits and nutritional products, today ... corn biotechnology product developed in China to ... regulatory trials. ...
(Date:2/22/2017)... N.C., Feb. 22, 2017  United Therapeutics Corporation (NASDAQ: ... results for the fourth quarter and year ended ... results reflect continued growth as net revenues reached ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and Chief ... to develop and advance our growing product pipeline, ...
Breaking Biology Technology:
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
Breaking Biology News(10 mins):